Method of treating the syndrome of coronary heart disease risk factors in humans
CA 2317155 A1 · Owner: Clemens Product Development (Cpd, Llc) · Inventors: Clemens, Anton H.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A method of treatment of humans suffering from the Coronary Heart Disease Risk Factor, (CHDRF) Syndrome which comprises the steps of: 1) administering by a , pharmaceutically, effective mode a priming dose of drug composition selected from the group consisting of opiate, antagonists, and drugs which substantially equally reduce the amounts of catecholamines bound, to catecholamine binding sites for a period of about one to four weeks and 2) , administering a, maintenance dose of said selected drug is disclosed.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 29, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended August 29, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 29, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.